Cervical Cancer

For cervical cancer awareness month, Lauren Bollinger, MD, discusses how the increase in research in the field of cervical cancer is driving the progress of treatment.

With 30 months additional follow-up on the EMPOWER-Cervical 1 trial, cemiplimab monotherapy showed efficacy in patients with metastatic cervical cancer.

Although PD-L1 expression has limitations as a predictive biomarker, it has nonetheless driven clinical decision-making.

Results from the KEYNOTE-826 trial showed that chemotherapy plus pembrolizumab with or without bevacizumab improved overall survival and progrssion-free survival in patients with metastatic cervical cancer based on subgroups including histology and prior treatment type.

In an interview with Targeted Oncology, David S. Hong, MD, discussed the mark tisotumab vedotin has made on the metastatic cervical cancer landscape thus far.